Back to All Events

[ON-DEMAND] WEBINAR: GER RWE studies with the brand-new nationwide FDZ-G dataset

[ON-DEMAND] WEBINAR: GER RWE studies with the brand-new nationwide FDZ-G dataset

Germany, as the biggest European pharmaceutical market, is certainly one of the key regions for RWE data generation if it comes to Europe. Since October 2025, access to a brand-new nation-wide claims dataset (“FDZ-G”) is possible. However, doing FDZ-G studies is associated with both procedural and content-related challenges which should be known before a study is kicked off. The GIPAM team is one of the first groups who managed to get access to FDZ-G, with two study readouts in April/May 2026. In this webinar, we will report how FDZ-G data could be used, what the challenges are and how to overcome these.

Key Takeaway:
Our experts, Prof. Dr. Thomas Wilke and Sabrina Müller will discuss the points below:

  • Which data are available?

  • How is „access to data“ granteds?

  • Data analysis: what is the model, how to develop the right algorithms?

  • Two example studies: first learnings

  • Main learnings

Event Details:

  • Date: 24th June 2026

  • Time: 16:00 – 17:00 Uhr (CET)

  • Language: English

Watch Now
Download Presentation

Speakers:

Prof. Dr. Thomas Wilke (Scientific Leader, GIPAM)

  • Over 20 years’ experience in managing real-world evidence (RWE) studies.

  • Head of IPAM Research Institute and former Global RWE Lead at Cytel.

  • Specialize in strategic evidence generation and RWE research activities.

 

Sabrina Müller, Msc (Managing Director, GIPAM EU)

  • Over 10 years of experience leading health economic RWE (Real-World Evidence) projects.

  • Expert in advanced database analytics, as well as adherence and preference studies.

  • Currently leading the implementation of pilot studies based on the FDZ-G data (Forschungsdatenzentrum Gesundheit).

 


Previous
June 17

Lunch Event: RWE-Studien mit FDZ-G-Daten: Erste Erfahrungen